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ABSTRACT.
Hyperactivation of NF-κB is a key factor in the pathophysiology of inflammatory bowel disease (IBD). We previously showed that the bile salt nuclear Farnesoid X Receptor (FXR)
counter-regulates intestinal inflammation, possibly via repression of NF-κB. Here, we examine whether mutual antagonism between NF-κB and FXR exists.
FXR and its target genes IBABP and FGF15/19 expression were determined in HT29 colon carcinoma cells and ex vivo in intestinal specimens of wild type (WT) and Fxr-ko mice, treated with/without FXR ligands (GW4064/INT-747) and inflammatory stimuli (TNFα/IL-1β). In addition, FXR activation was studied in vivo in WT and Fxr-ko mice with DSS-colitis.
The involvement of NF-κB in decreasing FXR activity was investigated by reporter assays and Glutathione S-transferase pulldown assays.
FXR target gene expression was highly reduced by inflammatory stimuli in all model
systems, while FXR mRNA expression was unaffected. In line with these results, reporter assays showed reduced FXR transcriptional activity upon TNFα/IL-1β stimulation. We show that this reduction in FXR activity is probably mediated by NF-κB, since overexpression of NF-κB subunits p50 and/or p65 also lead to inhibition of FXR activity. Finally, we report that p65 and p50 physically interact with FXR in vitro.
Conclusions: Together, these results indicate that intestinal inflammation strongly reduces FXR activation, probably via NF-κB-dependent tethering of FXR. Therefore, FXR not only inhibits inflammation, but also is targeted by the inflammatory response itself. This could result in a vicious cycle where reduced FXR activity results in less repression of inflammation, contributing to development of chronic intestinal inflammation.
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INTRODUCTION.

Inflammatory bowel disease (IBD), including Crohn disease (CD) and ulcerative colitis (UC),
is characterized by chronic intestinal inflammation, with potentially severe complications and even mortality. [1] Although the exact aetiology is unclear, it is thought to result from a combination of dysregulation of the mucosal immune system, hyper-reactive against the intestinal microbiota, and compromised intestinal epithelial barrier function in genetically predisposed individuals. [2] In IBD patients, the nuclear transcription Factor κappa B (NF-κB) was identified as a key factor in the pro-inflammatory response, resulting in strongly enhanced expression of pro-inflammatory genes and recruitment of excess inflammatory cells to the intestinal wall. [3] The NF-κB complex is a heterodimeric protein predominantly consisting of p65 and p50 sub-units. [4] In the absence of activating signals, the inhibitor protein IκBα retains NF-κB in the cytosol. Presence of pro-inflammatory cytokines (e.g.
TNFα, Il-1β), reactive oxygen species or viral products, initiates phosphorylation and subsequent degradation of IκBα, allowing NF-κB to translocate to the nucleus and directly regulate the expression of specific target genes. [5] The bile salt nuclear Farnesoid X Receptor (FXR) is a member of the superfamily of nuclear receptors. 
FXR activation decreases the severity of inflammation and preserves the intestinal barrier integrity in two well-established murine colitis models. [9] In recent years, reciprocal repression between several nuclear receptors (NR) and inflammatory pathways has been described. Activation of several NRs (e.g. Glucocorticoid Receptor, Androgen Receptor and Estrogen Receptor) inhibits inflammation, whereas activation of these nuclear receptors is highly reduced in inflamed tissues, suggesting that repression of nuclear receptors might be a mechanism required for inflammation to progress. [10] Also, FXR-mediated gene expression was shown to be suppressed during hepatic inflammation [11] and FXR mRNA expression was shown to be reduced in inflamed colonic mucosa in a small cohort of Crohn's patients. [12] In the current work, we provide in vitro, ex vivo and in vivo evidence that the inflammatory response reciprocally inhibits activation of FXR and its target genes in the intestine. These complementary findings may have important implications for intestinal inflammation and regulation of bile salt homeostasis in patients with inflammatory bowel disease.
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Reporter assays
HEK293T cells were grown in 96-multiwell plates and co-transfected with empty pGL3, pGL3-IBABP or pGL3-SHP reporters, tK-Renilla and either empty pcDNA or pcDNAhFXRα2 together with pcDNA-RXRα using the standard calcium phosphate method, as described elsewhere. [14] After 24 hours, cells were incubated with vehicle (DMSO) or 1 µM GW4064 for 24 hours, in presence or absence of either TNFα (500U/ml) or IL-1β (20ng/mL).
Alternatively, cells were co-transfected with NF-κB sub-units pcDNA-p50 and/or pcDNA- with the Centro LB 960 luminometer (Berthold Technologies, Vilvoorde, Belgium).
Glutathione S-Transferase (GST) Pull-down assay
GST-pull down experiments were performed as described elsewhere. 
Animals
Nine-to-twelve weeks old male wild type (WT) C57BL/6J mice were obtained from Charles 
Ex-vivo culturing of murine ileal specimens
Ileal samples of C57Bl/6 wild type (WT; n=4) and Fxr-ko (n=4) mice were collected, washed with PBS, divided into 6 pieces of approximately equal size and kept in culture for 24 hours at 37°C with 5% CO 2 in Dulbecco Modified Eagle's Medium (DMEM) GlutaMax™ (4.5 g/L DGlucose and Pyruvate; Gibco BRL, Breda, the Netherlands), supplemented with 10% heatinactivated fetal calf serum and 1% penicillin/streptomycin (Gibco BRL). The specimens were treated with DMSO, GW4064 (1µM) and/or either TNFα (500U/mL) or IL-1β (20ng/mL). After 24 hours mRNA was isolated (see below). 
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FXR activation and induction of murine colitis
mRNA extraction and qRT-PCR analysis
Ileal specimens were homogenized (Omni TH tissue homogenizer, Omni International, Kennesaw, USA) and RNA was isolated using RNeasy Micro kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions. The quantity, quality and integrity of isolated mRNA were confirmed by absorption measurement and RNA gel electrophoresis.
Subsequently cDNA was generated from 500 ng of total RNA using SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and random hexamers (Roche, Basel, Switzerland). qRT-PCR analysis was carried out using SYBR green PCR master mix (Biorad, Veenendaal, The Netherlands) and a MyIQ real time PCR cycler (Biorad). Values were quantified using the comparative threshold cycle method and FXR and target gene mRNA expression was normalized to GAPDH. Primers are listed in supplementary Table 1 .
Statistical analysis
Results are expressed as means ±SEM or ±SD as indicated in the figure legends. ANOVA or Student t test was performed as appropriate with GraphPad Software (GraphPad Software,
Inc., Avenida de la Playa, La Jolla, USA), as appropriate. Two-sided p-values <0.05 are considered statistically significant and are expressed as *p<0.05; **p<0.01 and ***p<0.001.
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RESULTS
TNFα inhibits FXR target gene expression in differentiated HT29 cells
To study the effects of an inflammatory stimulus on FXR target gene expression, we treated 
The pro-inflammatory cytokines TNFα and IL-1β inhibit FXR transcriptional activity
In order to investigate whether pro-inflammatory agents (TNFα and IL-1β) decrease suggesting that the inhibition of FXR target gene expression by these pro-inflammatory cytokines is due to a decrease in FXR transcriptional activity.
Overexpression of the NF-κB subunits p50 and p65 inhibits FXR transcriptional activity
Since TNFα and IL-1β activate NF-κB, we next explored whether NF-κB subunits (p50 and p65) directly affect FXR transcriptional activity. HEK293 cells were transfected with either pGL3-IBABP or pGL3-SHP promoter reporter constructs together with FXR and RXR in combination with either p50, p65 or both. The p50 subunit decreased GW4064-dependent IBABP and SHP promoter activity (by 42% and 85%, respectively) and p65 decreased GW4064-dependent IBABP and SHP promoter activities by 97% and 98%, respectively. Cotransfection of p50 and p65 completely abolished GW4064-dependent IBABP and SHP promoter activity ( Figure 3A and B). These results suggest that the inhibition of FXR transcriptional activity is mediated by NF-κB.
FXR interacts with the NFκB subunits p50 and p65 in a GST-pull down assay
To investigate whether the decrease of FXR transcriptional activity is due to physical interaction between FXR and the NF-κB subunits p50 and p65, a GST-pull down assay was performed. The NF-κB subunits p65 and p50 bind to FXR, in a ligand independent fashion ( Figure 3C ). Also, GST-pull down assays performed with GST-p65 fusion proteins and [35S]-labeled FXR, revealed interaction between FXR and the NF-κB subunit p65 ( Figure 3D ).
Fxr activation is inhibited by TNFα and IL-1β in ex-vivo ileal samples of WT and Fxr-ko mice
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To extrapolate our in vitro findings, we prepared ileal specimens from WT and Fxr-ko mice, and cultured them ex vivo in the presence or absence of GW4064 and either TNFα or IL-1β.
Fxr expression in the ileal specimens did not change under any of the described conditions 
Fxr activation is decreased in the ileum and colon of mice with DSS-induced colitis
To explore the inhibition of Fxr activity by inflammatory stimuli in vivo, we investigated whether DSS-induced inflammation inhibits Fxr-dependent gene expression in the ileal and colonic mucosa of WT and Fxr-ko mice. Fxr was expressed in WT mice, but not Fxr-ko mice. Based on these results, it can be anticipated that ablation of Fxr would lead to more severe intestinal inflammation. Indeed, we observed that Fxr-ko mice have severely impaired
intestinal integrity compared to WT mice at baseline (Supplementary Figure 3 of [9] ), suggesting that they are probably more susceptible to chronic inflammation. However, we did not find more severe colitis in Fxr-ko mice than in wild type mice treated with DSS. This may relate to the short duration of the DSS protocol, the young age of the mice and/or the microenvironmental conditions. It is also possible that the severe inflammation in the DSS model does not allow detecting subtle differences between Fxr-ko and wild type mice.
This study shows that FXR is not only an active player in inhibition of inflammation, but also is a target of the inflammatory response itself. This could result in a vicious cycle where reduced FXR activity results in less repression of intestinal inflammation, contributing to development of chronic intestinal inflammation. Together, these findings imply an important role for FXR in the protection against IBD. We also hypothesize that decreased FXR activity may lead to altered bile salt enterohepatic circulation and potentially relate to cholestatic liver disease, which often coexists in patients with inflammatory bowel disease. [20] In recent years, a reciprocal regulation between several steroid NRs on the one hand and inflammatory pathways on the other hand has been described. Little is known about the exact mechanisms underlying these processes. For example, NF-κB has been shown to suppress PXR regulated gene expression, by interfering with the binding of PXR to the PXR
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15 responsive element. [21] In the current study, we also show direct involvement of NF-κB in repression of FXR activity, since overexpression of NF-κB subunits p50 and p65 inhibits FXR activity and has the ability to physically interact with FXR. Similarly to PXR, NF-κB may inhibit FXR activation by preventing binding of FXR to its cognate FXR responsive element in the DNA. However, at this stage, we cannot rule out other potential mechanisms such as the competition between the nuclear receptor and the NF-κB complex for a common transcriptional cofactor ("cofactor squelching").
It has long been appreciated that inflammation affects bile homeostasis and that bile salts have immune suppressive actions. Although additional mechanisms may exist, our work provides insights in the mechanisms by which bile salts interact with the immune system via FXR.
CONCLUSION
In this paper we show that in addition to the role of FXR in counter-regulation of the intestinal inflammatory response, [9] there is reciprocal inhibition of the FXR pathway by the inflammatory response. We provide evidence for involvement of NF-κB in this suppressive effect. The crosstalk between NF-κB and FXR at the intestinal level indicates an interaction between lipid metabolism and inflammatory disease and leads to new insights in pathogenesis and potentially also to novel treatment strategies for inflammatory bowel disease. and Fxr-ko mice (grey bars). Each bar represents the mean value ± SEM. **p<0.01, ***p<0.001 compared to WT INT-747-treated mice. 
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